



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/725,965	12/02/2003	Erik Buntinx	29248/18	2844
1912	7590	03/13/2007	EXAMINER	
AMSTER, ROTHSTEIN & EBENSTEIN LLP			RAMACHANDRAN, UMAMAHESWARI	
90 PARK AVENUE			ART UNIT	PAPER NUMBER
NEW YORK, NY 10016			1617	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
31 DAYS	03/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/725,965	BUNTINX, ERIK	
	Examiner	Art Unit	
	Umamaheswari Ramachandran	1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 06 May 2004.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 32-77 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 32-77 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application

6) Other: _____

DETAILED ACTION

Claims 32-77 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 32-40 are drawn to a method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a compound (i) a selective affinity for the Dopamine-4 (D4) receptor and (ii) a selective affinity for the 5-HT2A receptor, classified in class 514, subclass 317.
- II. Claims 41-42 are drawn to a pharmaceutical composition comprising a (a) compound having (i) a selective affinity for the Dopamine-4 (D4) receptor (ii) a selective affinity for the 5-HT2A receptor (b) a selective serotonin re-uptake inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality, classified in class 514, subclass 317.
- III. Claims 43-50, drawn to method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a first compound having (i) a selective affinity for the Dopamine-4 (D4) receptor, and a second compound having (ii) a selective affinity for the 5-HT2A receptors, classified in class 514, subclass 317.

- IV. Claim 51 drawn to a pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor (b) a compound having a selective affinity for the 5-HT2A receptor and (c) a selective serotonin re-uptake inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality, classified in class 514, subclass 317.
- V. Claims 52, 54, 56 drawn to a method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a compound as defined in claim 32 where the compound is administered simultaneously with, separate from or sequential to administering a nor-epinephrine re-uptake inhibitor to said patient to augment the therapeutic effect of said nor-epinephrine re-uptake inhibitor or to provide a faster onset of the therapeutic effect of said nor-epinephrine re-uptake inhibitor, classified in class 514, subclass 317.
- VI. Claims 53, 55, 57 drawn to a method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a first compound and a second Compound as defined in claim 43 where said compounds are administered simultaneously with, separate from or sequential to administering a nor-epinephrine re-uptake inhibitor to said patient to augment the therapeutic effect of said nor-epinephrine re-uptake inhibitor or to provide a faster

onset of the therapeutic effect of said nor-epinephrine re-uptake inhibitor, classified in class 514, subclass 317.

VII. Claim 58 is drawn to a pharmaceutical composition comprising:

(a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor and (ii) a selective affinity for the 5-HT2A receptor (b) a nor-epinephrine re-uptake inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality, classified in class 514, subclass 317.

VIII. Claim 59 is drawn to a pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor (b) a compound having a selective affinity for the 5-HT2A receptor with a (c) a nor-epinephrine re-uptake inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality, classified in class 514, subclass 317.

IX. Claim 60, 62, 64 are drawn to a method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a compound as defined in claim 32 where said compound is administered simultaneously with, separate from or sequential to administering a neuroleptic agent to said patient to augment the therapeutic effect of said neuroleptic agent or to provide a

faster onset of the therapeutic effect of said neuroleptic agent, classified in class 514, subclass 317.

- X. Claims 61, 63, 65 are drawn to a method for treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a first compound and a second compound as defined in claim 43 where said compounds are administered simultaneously with, separate from or sequential to administering a neuroleptic agent to said patient to augment the therapeutic effect of said neuroleptic agent or to provide a faster onset of the therapeutic effect of said neuroleptic agent, classified in class 514, subclass 317.
- XI. Claim 66 is drawn to a pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor and (ii) a selective affinity for the 5-HT2A receptor and (b) a neuroleptic agent, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality, classified in class 514, subclass 317.
- XII. Claim 67 is drawn to a pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor (b) a compound having a selective affinity for the 5-HT2A receptor and (c) a neuroleptic agent, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an

underlying dysregulation of the emotional functionality, classified in class 514, subclass 317.

XIII. Claims 68, 70, 72 are drawn to a method for treating a muscoskeletal disease or disorder comprising administering to a patient a compound as defined in claim 32 where said compound is administered simultaneously with, separate from or sequential to administering a COX-2 inhibitor to said patient to augment the therapeutic effect of said COX-2 inhibitor or to provide a faster onset of the therapeutic effect of said COX-2 inhibitor, classified in class 514, subclass 317.

XIV. Claims 69, 71, 73 are drawn to a method for treating a muscoskeletal disease or disorder comprising administering to a patient a first compound and a second compound as defined in claim 43 where said compounds are administered simultaneously with, separate from or sequential to administering a COX-2 inhibitor to said patient to augment the therapeutic effect of said COX-2 inhibitor or to provide a faster onset of the therapeutic effect of said COX-2 inhibitor, classified in class 514, subclass 317.

XV. Claim 74 is drawn to a pharmaceutical composition comprising:
(a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor and (b) a COX-2 inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a muscoskeletal disease or disorder, classified in class 514, subclass 317.

XVI. Claim 75 is drawn to pharmaceutical composition comprising (a) a compound having a selective affinity for the Dopamine-4 (D4) receptor (b) a compound having a selective affinity for the 5-HT2A (c) a COX-2 inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a muscoskeletal disease or disorder, classified in class 514, subclass 317.

XVII. Claims 76 and 77 are drawn to a method for preparing a compound having a selective Dopamine-4 (D4) and 5-HT2A antagonist, reverse agonist or partial agonist activity comprising the following steps:

- (a) measuring the selective affinity of a test compound to the D4 receptor and measuring the selective efficacy of the selected compound to the D4 receptor and selecting a compound, which is a selective antagonist, inverse agonist or partial agonist of the D4 receptor;
- (b) measuring the selective affinity of a test compound to the 5-HT2A receptor and measuring the selective efficacy of the selected compound to the 5-HT2A receptor and selecting a compound, which is a selective antagonist, inverse agonist or partial agonist of the 5-HT2A receptor;
- (c) identifying a compound which is selected in (a) and (b); and
- (d) preparing the compound identified in (c), classified in class 514, subclass 317.

The inventions of Groups I, III, V, VI, X, XIII, XIV and Groups II, IV, VII, VIII, IX, XI, XII, XV, XVI and Group XVII are related to each other as

method of use, pharmaceutical composition and method of making a compound. The inventions are distinct if the following can be shown: (1) that the method as claimed can be carried out with a different product or (2) that the product as claimed can be used for a different method. (See MPEP § 806.05(h). In the instant case the method in the claims can tripropylacetic acid derivatives (FR 2278323) in the treatment of a disease or a disorder associated with emotional functionality and androstane carboxylic acid ester compounds can be used in the treatment of muscoskeletal disorders (U.S. 4,804,656).

The inventions of Groups I, III, V, VI, X, XIII, XIV are related to each other as method of treatment of disorder or disease associated with emotional functionality or muscoskeletal disorder and Groups II, IV, VII, VIII, IX, XI, XII, XV, XVI are related to each other pharmaceutical composition and Group XVII is a method of making a compound.

The searches of Groups I-XVII may be overlapping but there is no reason to believe that the searches would be co-extensive. Because these inventions are distinct for the reasons given above and the search required for one group is not required for other groups restriction for examination purposes as indicated is proper. In searching for Groups I, III, V, VI, X, XIII, XIV, the examiner will be focusing on the method of method of treatment of disorder or disease associated with emotional functionality or muscoskeletal disorder whereas in searching for Groups II, IV, VII, VIII,

IX, XI, XII, XV, XVI examiner will be focusing on the pharmaceutical compositions. The search for all inventions would place an undue burden on the Office in view of the corresponding diversity in the field of search for each.

The examiner has required restriction between process and product claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection is governed by 37 CFR 1.116; amendments submitted after allowance is governed by 37 CFR 1.312. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between products claims and process claims may be

maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

The application contains claims directed to patentably distinct species of the claimed invention. If Applicant elects Group I Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and 5-H2T2A receptor and a species of the second compound. If Applicant elects Group II Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and 5-H2T2A receptor and a species of serotonin re-uptake inhibitor. If Applicant elects Group III Applicant is required to elect a species of a compound having a selective affinity for the dopamine

receptor-4 and a species of a compound having a selective affinity for 5-H2T2A receptor (second compound) and a species of the disorder and a species of the third compound. If Applicant elects Group IV Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and a species of a compound having selective affinity for the 5-H2T2A receptor and a species of serotonin re-uptake inhibitor. If Applicant elects Group V Applicant is required to elect a species of a species of compound having a selective affinity for the dopamine receptor-4 and 5-H2T2A receptor and a species of a nor-epinephrine re-uptake inhibitor and a species of the disease or disorder. If Applicant elects Group VI Applicant is required to elect a species of a compound having a selective affinity for the dopamine receptor-4 and a species of a compound having selective affinity 5-H2T2A receptor (second compound) and a species of the disorder or disease and a species of a nor-epinephrine re-uptake inhibitor. If Applicant elects Group VII Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and 5-H2T2A receptor and a species of a nor-epinephrine re-uptake inhibitor. If Applicant elects Group VIII Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and a species of compound having a selective affinity for 5-H2T2A receptor and

a species of a nor-epinephrine re-uptake inhibitor. If Applicant elects Group IX or XI Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and 5-H2T2A receptor and a species of a neuroleptic agent. If Applicant elects Group X or XII Applicant is required to elect a species of a disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and a species of a compound having a selective affinity for the 5-H2T2A receptor and a species of neuroleptic agent. If Applicant elects Group XIII or Group XV Applicant is required to elect a species of a muscoskeletal disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and 5-H2T2A receptor and a species of a COX-2 inhibitor. If Applicant elects Group XIV or XVI Applicant is required to elect a species of a muscoskeletal disease or a disorder, a species of compound having a selective affinity for the dopamine receptor-4 and a species of compound having a selective affinity for the 5-H2T2A receptor and a species of a COX-2 inhibitor. If Applicant elects Group XVII Applicant is required to elect a species of the compound.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in

the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C 103(a) of the other invention.

Election

A telephone call to the attorney is not required where 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the examiner knows from past experience that a telephone election will not be made (MPEP § 812.01). Therefore, since the examiner knows from past experience that written restriction is preferred, a telephone election was not made.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Umamaheswari Ramachandran whose telephone number is 571-272-9926. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER